Valence ロゴ
人気
ログイン

ウォッチリストに追加
Proチャート

Veraxa Biotech AG

NasdaqGM: VRXA · リアルタイム株価 · USD
1.87
-0.02 (-1.06%)
終値時点： Aug 14, 2026, 3:59 PM
1.87
+0.24%
時間外: 4:56 PM

Veraxa Biotech AG (VRXA) Stock Price, Analysis & Data

-1.06%
買気配1.85
時価総額271.62M
売上高（TTM）n/a
純利益（TTM）n/a
ベータn/a
EPS（TTM）-0.58
PER（TTM）n/a
予想PERn/a
PBR（TTM）n/a
PSR（TTM）n/a
Earnings Daten/a
売気配1.9
出来高187,635
平均出来高（20日）458,509
始値1.91
前日終値1.89
当日レンジ1.84 - 1.93
52週レンジ1.70 - 27.36
アナリストn/a
目標株価n/a
配当n/a
権利落ち日n/a

VRXAについて

VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partn...

[続きを読む]
業種 Biotechnology
セクター Healthcare
IPO日 Sep 30, 2024
従業員数 n/a
上場取引所 NasdaqGM
ティッカー VRXA
ウェブサイト https://www.veraxa.com
企業情報の全文

業績

2025年のVeraxa Biotechの売上高は23.43Kで、前年の0からundefined%の増加でした。 利益は-66.61Mで、136.78%の増加でした。

財務諸表
news image

1か月前 · Exec Edge

The Cancer Therapy Strategy VERAXA Is Betting the Company On

By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it expects BiTAC molecules to be the company’s main value drivers and to dominate its pipeline development in the upcoming years, hence receiving V...

news image

1か月前 · Exec Edge

VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone

By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it started cell line development for its lead BiTAC T-cell engager program, collaborating with ATUM to apply proprietary technology for stable clon...

news image

1か月前 · Exec Edge

VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development

By Daniella Parra VERAXA Biotech AG (Nasdaq: VRXA)has expanded its R&D facility in Heidelberg, Germany, increasing laboratory space by more than 60% to support team growth and accelerate its cancer th...

news image

1か月前 · Exec Edge

VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026

By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) reported in vitro proof-of-concept data validating its BiTAC-ADC platform for cancer therapies, with selective tumor cell killing while sparing healthy ...